| scholarly article | Q13442814 |
| P50 | author | Hanne Lindegaard | Q43073193 |
| Merete Lund Hetland | Q56223933 | ||
| P2093 | author name string | Ib Jarle Christensen | |
| Mikkel Østergaard | |||
| Annette Hansen | |||
| Ulrik Tarp | |||
| Lene Dreyer | |||
| Louise Linde | |||
| Gisela Hostenkamp | |||
| All Departments of Rheumatology in Denmark | |||
| Annette Schlemmer | |||
| Dorte Vendelbo Jensen | |||
| Gina Kollerup | |||
| Ib Tønder Hansen | |||
| Signe Jensen | |||
| Uta Engling Poulsen | |||
| P2860 | cites work | Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis | Q37007690 |
| P433 | issue | 1 | |
| P921 | main subject | patient | Q181600 |
| rheumatoid arthritis | Q187255 | ||
| adalimumab | Q348260 | ||
| P304 | page(s) | 22-32 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D | |
| P478 | volume | 62 |
| Q28551075 | A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients |
| Q38628540 | A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study |
| Q46326827 | A prospective study of anti-tumor necrosis factor therapy in South African rheumatoid arthritis patients. |
| Q36496107 | A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years |
| Q47367453 | A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population. |
| Q99608557 | A shedding soluble form of interleukin-17 receptor D exacerbates collagen-induced arthritis through facilitating TNF-α-dependent receptor clustering |
| Q38662236 | A systematic review of the barriers affecting medication adherence in patients with rheumatic diseases. |
| Q34752154 | Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. |
| Q35974381 | Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry |
| Q38082233 | Active immunotherapy for chronic diseases |
| Q38192659 | Adalimumab in the treatment of rheumatoid arthritis |
| Q37777418 | Adherence to biologic DMARD therapies in rheumatoid arthritis |
| Q21093257 | Advances in rheumatology: new targeted therapeutics |
| Q35415667 | An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. |
| Q38344282 | Anti-TNF in rheumatoid arthritis: an overview |
| Q91268857 | Anti-TNF treatment negatively regulates human CD4+ T-cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype |
| Q28540052 | Anti-TNF treatment response in rheumatoid arthritis patients is associated with genetic variation in the NLRP3-inflammasome |
| Q37808969 | Anti-inflammatory glucocorticoid drugs: reflections after 60 years |
| Q89099159 | Are We Able to Suppress Disease Activity Adequately in Patients With Established Rheumatoid Arthritis? An Observational and Cross-Sectional Study |
| Q39042968 | Arthroscopic guided synovial biopsy in rheumatology: current perspectives |
| Q38842054 | Assessment of Confounders in Comparative Effectiveness Studies From Secondary Databases |
| Q53654897 | Assessment of the effectiveness of golimumab 50-mg and 100-mg regimens in patients with rheumatoid arthritis in daily practice. |
| Q89983758 | Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis |
| Q30234303 | Biologics registers in RA: methodological aspects, current role and future applications |
| Q28728734 | CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis |
| Q48105240 | CDK7 inhibition suppresses rheumatoid arthritis inflammation via blockage of NF-κB activation and IL-1β/IL-6 secretion |
| Q33968506 | Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: results from the ABRAB study |
| Q85522624 | Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure |
| Q39420995 | Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. |
| Q36331865 | Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. |
| Q38424589 | Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis |
| Q37445629 | Comparative effectiveness of infliximab and adalimumab for Crohn's disease |
| Q84587921 | Comparative effectiveness of rheumatoid arthritis therapies |
| Q61810043 | Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study |
| Q57330054 | Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis |
| Q31077662 | Comparative effectiveness research with administrative health data in rheumatoid arthritis |
| Q28542423 | Comparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort study |
| Q48026614 | Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab |
| Q27679553 | Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View |
| Q50608134 | Compliance with treatment of rheumatoid arthritis. |
| Q39326581 | Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis |
| Q28484306 | Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china |
| Q36776326 | Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers |
| Q38133655 | Current immunotherapy in rheumatoid arthritis |
| Q36996859 | Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review |
| Q37819496 | DANBIO--powerful research database and electronic patient record |
| Q35840753 | Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis |
| Q40787850 | Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis |
| Q36302246 | Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors? |
| Q42041036 | Disentangling Rheumatoid Arthritis Patients' Implicit and Explicit Attitudes toward Methotrexate |
| Q38650525 | Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis |
| Q36830635 | Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs |
| Q38338700 | Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review |
| Q36194054 | Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept |
| Q41693369 | Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register |
| Q52653996 | Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study. |
| Q51036235 | Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL. |
| Q38664981 | Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry. |
| Q49370571 | Drug survival and the associated predictors in South Korean patients with rheumatoid arthritis receiving tacrolimus |
| Q38406712 | Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. |
| Q35048347 | Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab |
| Q34208252 | Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis |
| Q64053097 | Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study |
| Q64062693 | Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study |
| Q36274355 | Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis |
| Q36267465 | EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry |
| Q92771523 | Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study |
| Q38250160 | Economics of non-adherence to biologic therapies in rheumatoid arthritis. |
| Q40735887 | Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry |
| Q41662059 | Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register |
| Q46131525 | Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register |
| Q51209335 | Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. |
| Q48253106 | Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs |
| Q64101588 | Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or |
| Q37653421 | Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events |
| Q92737334 | Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry |
| Q40813632 | Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population |
| Q52841141 | Etanercept in the treatment of rheumatoid arthritis. |
| Q38230740 | Etanercept: a review of its use in autoimmune inflammatory diseases |
| Q35620336 | Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors |
| Q41908486 | Evaluation of Anti-inflammatory Effects of Steroids and Arthritis-Related Biotherapies in an In Vitro Coculture Model with Immune Cells and Synoviocytes |
| Q36795982 | Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort |
| Q30725001 | Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry |
| Q37587403 | Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study |
| Q39568753 | Fatigue, pain and patient global assessment responses to biological treatment are unpredictable, and poorly inter-connected in individual rheumatoid arthritis patients followed in the daily clinic |
| Q43675571 | Guidelines for the drug treatment of rheumatoid arthritis |
| Q35247643 | Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis |
| Q36216285 | Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis. |
| Q38120525 | How to translate basic knowledge into clinical application of biologic therapy in spondyloarthritis |
| Q37529057 | HtrA2 suppresses autoimmune arthritis and regulates activation of STAT3. |
| Q35627436 | Identification of anti-inflammatory fractions of Geranium wilfordii using tumor necrosis factor-alpha as a drug target on Herbochip® - an array-based high throughput screening platform |
| Q48508515 | Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study. |
| Q47380976 | Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment |
| Q26798357 | Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice |
| Q35547487 | Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients |
| Q50262782 | Improved safety of biologic therapy for rheumatoid arthritis over the 8-year period since implementation in Japan: long-term results from a multicenter observational cohort study |
| Q60049864 | Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results |
| Q59546338 | Infliximab therapy efficacy and persistence at a Canadian academic centre despite a change in access procedure |
| Q49693642 | Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis |
| Q90049984 | Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study |
| Q34237578 | Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study |
| Q40926392 | Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis |
| Q44247481 | Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice? |
| Q36575283 | Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis? |
| Q45805620 | Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort. |
| Q34276089 | JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy |
| Q33766353 | Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis |
| Q37338261 | Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers |
| Q38404761 | Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice |
| Q45970934 | Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. |
| Q35132715 | Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension |
| Q64880486 | Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behçet's disease. |
| Q88687872 | Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data |
| Q37034034 | Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review |
| Q35605418 | MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial |
| Q89458696 | Management of inflammatory rheumatic conditions in the elderly |
| Q38915704 | Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil |
| Q49679549 | Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation |
| Q38804610 | Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France |
| Q26824970 | Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors |
| Q31059883 | Non-nociceptive pain in rheumatoid arthritis is frequent and affects disease activity estimation: cross-sectional data from the FRAME study. |
| Q47917968 | Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience |
| Q48302611 | Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up |
| Q96133864 | Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis |
| Q38663329 | Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region |
| Q34022346 | Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study |
| Q39702204 | Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. |
| Q38084444 | Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine |
| Q38167894 | Pharmacogenomics of biological treatment in rheumatoid arthritis |
| Q37690033 | Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. |
| Q37118948 | Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab |
| Q39011089 | Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis. |
| Q40864639 | Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry |
| Q55376762 | Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. |
| Q35577993 | Predictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease. |
| Q39668241 | Predictors of long-term drug survival for infliximab in psoriasis. |
| Q37514466 | Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis |
| Q34264302 | Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort |
| Q39453656 | Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levels |
| Q38431249 | Protective and detrimental roles of inflammasomes in disease |
| Q50129702 | Proteinases and their receptors in inflammatory arthritis: an overview |
| Q26778600 | Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases |
| Q40179378 | Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences |
| Q58775879 | Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis |
| Q64113326 | Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature |
| Q30769719 | Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data |
| Q30612998 | Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data |
| Q43444262 | Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. |
| Q47810854 | Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience. |
| Q57741141 | Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis |
| Q98612944 | Rheumatoid Arthritis Saudi Database (RASD): Disease Characteristics and Remission Rates in a Tertiary Care Center |
| Q28073099 | Rheumatoid arthritis: identifying and characterising polymorphisms using rat models |
| Q51245791 | Role of Diet in Influencing Rheumatoid Arthritis Disease Activity. |
| Q38827889 | Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance |
| Q37691205 | Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study |
| Q35999139 | Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis |
| Q42578542 | Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis |
| Q30891297 | Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries |
| Q38755912 | Selected cytokine pathways in rheumatoid arthritis |
| Q34027422 | Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity |
| Q47687376 | Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register |
| Q37954363 | Small molecular therapies for rheumatoid arthritis: where do we stand? |
| Q39694655 | Stability of clinical outcome measures in rheumatoid arthritis patients with stable disease defined on the basis of the EULAR response criteria |
| Q47211643 | Stability of fatigue, pain, patient global assessment and the Bath Ankylosing Spondylitis Functional Index (BASFI) in spondyloarthropathy patients with stable disease according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). |
| Q47633961 | Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab |
| Q60919476 | Switching of biological therapies in Brazilian patients with rheumatoid arthritis |
| Q40314992 | Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry. |
| Q38728689 | Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. |
| Q33400381 | Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor |
| Q37642265 | TNF Blockade Maintains an IL-10+ Phenotype in Human Effector CD4+ and CD8+ T Cells |
| Q28972424 | TNF inhibitor therapy for rheumatoid arthritis |
| Q41830089 | TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy. |
| Q28073436 | Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs |
| Q85932909 | Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides |
| Q52656669 | Testing the potency of anti-TNF-α and anti-IL-1β drugs using spheroid cultures of human osteoarthritic chondrocytes and donor-matched chondrogenically differentiated mesenchymal stem cells. |
| Q33775593 | The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice |
| Q28076075 | The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO |
| Q92662245 | The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis |
| Q48265755 | The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. |
| Q36410046 | The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population |
| Q84992546 | The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice |
| Q38222900 | The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences |
| Q38033127 | The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists |
| Q45749970 | The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure |
| Q46081724 | The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort. |
| Q38069473 | The importance of rheumatology biologic registries in Latin America |
| Q36064093 | The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. |
| Q40206740 | The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. |
| Q37974121 | The practical value of biologics registries in Africa and Middle East: challenges and opportunities |
| Q38826447 | Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link. |
| Q38238931 | Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides |
| Q34724711 | Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial |
| Q47978774 | Tocilizumab (Actemra). |
| Q44818742 | Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial |
| Q50034711 | Transcriptional Profiling of Synovial Macrophages using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis. |
| Q53123438 | Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn's Disease Patients. |
| Q38034134 | Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings |
| Q50553120 | Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. |
| Q64241347 | Tumor Necrosis Factor Inhibitor Therapy and the Risk for Depression Among Working-Age Adults with Rheumatoid Arthritis |
| Q41260795 | Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study |
| Q53650686 | Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. |
| Q31021097 | Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. |
| Q44288102 | Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice |
| Q48503586 | Using technology to support clinical care and research in rheumatoid arthritis |
| Q47104450 | Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry |
| Q92132694 | What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis? |
| Q38027571 | When is switching warranted among biologic therapies in rheumatoid arthritis? |
| Q38068590 | Why is biologic therapy useful in spondyloarthritis? Knowledge from synovial immunopathologic studies of spondyloarthritis |
| Q91926031 | Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis |
| Q38207759 | anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. |
Search more.